Full Press Release Details
The stock options were granted with a 10-year term and an exercise price equal to $27.46 , the closing price per share of Spyre's common stock as reported by Nasdaq on October 1, 2024 . The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee's start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
For Investor s : Eric McIntyre VP of Finance and Investor Relations Spyre Therapeutics [email protected]
For Media : Peg Rusconi [email protected]
SOURCE Spyre Therapeutics, Inc.